In this analysis of individuals with obesity aged 65 years and older, semaglutide reduced body weight and improved cardiometabolic risk factors compared with placebo, and the safety and efficacy profile of semaglutide was consistent with that reported in the STEP programme." Prof Luca Busetto, University of Padova, Italy He adds: "In many countries, including many high-income countries, the majority of the cases of excess weight actually occur in adults aged 65 years and over, representing a major driver for obesity-related complications and an important cause of reduced quality of life and disability
O.KrzesinskiJ
Warnings Consult with your healthcare practitioner prior to use
Many GLP-1 medications reduce appetite significantly, and people on retatrutide may eat substantially less, increasing the risk of micronutrient deficiencies
others, however, expend only a fraction of the work they are willing to do in a restricted state (low-responders) (Dickson et al., ad libitum fed rats may interact with GLP-1R-driven reward responses